Skip to main content

Congenital Erythropoietic Porphyria

1
Pipeline Programs
1
Companies
2
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Atlas Molecular Pharma
1 program
1
ciclopiroxPhase 1/22 trials
Active Trials
NCT07024316Recruiting6Est. Jun 2028
NCT05647343Completed42Est. Apr 2024

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
2027
2028
Atlas Molecular Pharmaciclopirox
Atlas Molecular Pharmaciclopirox

Clinical Trials (2)

Total enrollment: 48 patients across 2 trials

NCT07024316Atlas Molecular Pharmaciclopirox

A Study to Investigate the Improvement of Photosensitivity in Terms of Skin Lesions Associated With CEP Following Administration of Oral ATL-001 (Ciclopirox Oral Solution) in Participants Aged >18 Years of Age With CEP

Start: Jan 2026Est. completion: Jun 20286 patients
Phase 1/2Recruiting
NCT05647343Atlas Molecular Pharmaciclopirox

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

Start: Mar 2023Est. completion: Apr 202442 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 actively recruiting trials targeting 48 patients
1 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.